Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T23172
(Former ID: TTDC00084)
|
|||||
Target Name |
Janus kinase 3 (JAK-3)
|
|||||
Synonyms |
Tyrosine-protein kinase JAK3; Leukocyte janus kinase; L-JAK
Click to Show/Hide
|
|||||
Gene Name |
JAK3
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 4 Target-related Diseases | + | ||||
1 | Alopecia ICD-11: ED70 | |||||
2 | Atopic eczema [ICD-11: EA80] | |||||
3 | Myeloproliferative neoplasm [ICD-11: 2A20] | |||||
4 | Rheumatoid arthritis [ICD-11: FA20] | |||||
Function |
Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion. Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation.
Click to Show/Hide
|
|||||
BioChemical Class |
Kinase
|
|||||
UniProt ID | ||||||
EC Number |
EC 2.7.10.2
|
|||||
Sequence |
MAPPSEETPLIPQRSCSLLSTEAGALHVLLPARGPGPPQRLSFSFGDHLAEDLCVQAAKA
SGILPVYHSLFALATEDLSCWFPPSHIFSVEDASTQVLLYRIRFYFPNWFGLEKCHRFGL RKDLASAILDLPVLEHLFAQHRSDLVSGRLPVGLSLKEQGECLSLAVLDLARMAREQAQR PGELLKTVSYKACLPPSLRDLIQGLSFVTRRRIRRTVRRALRRVAACQADRHSLMAKYIM DLERLDPAGAAETFHVGLPGALGGHDGLGLLRVAGDGGIAWTQGEQEVLQPFCDFPEIVD ISIKQAPRVGPAGEHRLVTVTRTDNQILEAEFPGLPEALSFVALVDGYFRLTTDSQHFFC KEVAPPRLLEEVAEQCHGPITLDFAINKLKTGGSRPGSYVLRRSPQDFDSFLLTVCVQNP LGPDYKGCLIRRSPTGTFLLVGLSRPHSSLRELLATCWDGGLHVDGVAVTLTSCCIPRPK EKSNLIVVQRGHSPPTSSLVQPQSQYQLSQMTFHKIPADSLEWHENLGHGSFTKIYRGCR HEVVDGEARKTEVLLKVMDAKHKNCMESFLEAASLMSQVSYRHLVLLHGVCMAGDSTMVQ EFVHLGAIDMYLRKRGHLVPASWKLQVVKQLAYALNYLEDKGLPHGNVSARKVLLAREGA DGSPPFIKLSDPGVSPAVLSLEMLTDRIPWVAPECLREAQTLSLEADKWGFGATVWEVFS GVTMPISALDPAKKLQFYEDRQQLPAPKWTELALLIQQCMAYEPVQRPSFRAVIRDLNSL ISSDYELLSDPTPGALAPRDGLWNGAQLYACQDPTIFEERHLKYISQLGKGNFGSVELCR YDPLGDNTGALVAVKQLQHSGPDQQRDFQREIQILKALHSDFIVKYRGVSYGPGRQSLRL VMEYLPSGCLRDFLQRHRARLDASRLLLYSSQICKGMEYLGSRRCVHRDLAARNILVESE AHVKIADFGLAKLLPLDKDYYVVREPGQSPIFWYAPESLSDNIFSRQSDVWSFGVVLYEL FTYCDKSCSPSAEFLRMMGCERDVPALCRLLELLEEGQRLPAPPACPAEVHELMKLCWAP SPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLSFS Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
HIT2.0 ID | T74QOR |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 4 Approved Drugs | + | ||||
1 | Abrocitinib | Drug Info | Approved | Atopic dermatitis | [2] | |
2 | Pacritinib | Drug Info | Approved | Myelofibrosis | [3] | |
3 | Ritlecitinib | Drug Info | Approved | Alopecia areata | [4] | |
4 | Tofacitinib | Drug Info | Approved | Rheumatoid arthritis | [1], [5], [6] | |
Clinical Trial Drug(s) | [+] 12 Clinical Trial Drugs | + | ||||
1 | ASP-015K | Drug Info | Phase 3 | Psoriasis vulgaris | [7], [8] | |
2 | VX-509 | Drug Info | Phase 2/3 | Rheumatoid arthritis | [9], [10] | |
3 | ATI-501 | Drug Info | Phase 2 | Alopecia | [11] | |
4 | ATI-502 | Drug Info | Phase 2 | Atopic dermatitis | [12] | |
5 | Cerdulatinib | Drug Info | Phase 2 | B-cell lymphoma | [13] | |
6 | TD-8236 | Drug Info | Phase 2 | Asthma | [14] | |
7 | ALXN2075 | Drug Info | Phase 1/2 | Non-hodgkin lymphoma | [15] | |
8 | AZD4604 | Drug Info | Phase 1 | Asthma | [16] | |
9 | GDC-0214 | Drug Info | Phase 1 | Asthma | [17] | |
10 | KN-002 | Drug Info | Phase 1 | Severe asthma | [18] | |
11 | PF-07295324 | Drug Info | Phase 1 | Atopic dermatitis | [19] | |
12 | SNA-125 | Drug Info | Phase 1 | Atopic dermatitis | [20] | |
Discontinued Drug(s) | [+] 3 Discontinued Drugs | + | ||||
1 | AG490 | Drug Info | Terminated | Multiple myeloma | [21], [22] | |
2 | PNU156804 | Drug Info | Terminated | Renal transplantation | [23] | |
3 | R348 | Drug Info | Terminated | Psoriasis vulgaris | [24] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Inhibitor | [+] 94 Inhibitor drugs | + | ||||
1 | Abrocitinib | Drug Info | [2] | |||
2 | Ritlecitinib | Drug Info | [4] | |||
3 | ASP-015K | Drug Info | [25] | |||
4 | VX-509 | Drug Info | [26], [27] | |||
5 | ATI-501 | Drug Info | [28] | |||
6 | ATI-502 | Drug Info | [12] | |||
7 | Cerdulatinib | Drug Info | [20] | |||
8 | TD-8236 | Drug Info | [29] | |||
9 | ALXN2075 | Drug Info | [30] | |||
10 | AZD4604 | Drug Info | [31] | |||
11 | GDC-0214 | Drug Info | [32] | |||
12 | KN-002 | Drug Info | [33] | |||
13 | PF-07295324 | Drug Info | [34] | |||
14 | SNA-125 | Drug Info | [20] | |||
15 | 1,2,4-triazolo[1,5a]pyridine derivative 1 | Drug Info | [35] | |||
16 | Aminooxazole carboxamide derivative 1 | Drug Info | [36] | |||
17 | Aminotriazolopyridine derivative 1 | Drug Info | [35] | |||
18 | Benzimidazole derivative 5 | Drug Info | [36] | |||
19 | Benzimidazole derivative 7 | Drug Info | [35] | |||
20 | Bis-aminopyrimidine derivative 1 | Drug Info | [35] | |||
21 | Bis-aminopyrimidine derivative 2 | Drug Info | [35] | |||
22 | Bis-aminopyrimidine derivative 3 | Drug Info | [35] | |||
23 | Bis-aminopyrimidine derivative 4 | Drug Info | [35] | |||
24 | Five-and-six-membered heterocyclic compound 1 | Drug Info | [36] | |||
25 | Imidazopyridazine derivative 1 | Drug Info | [35] | |||
26 | Imidazopyridazine derivative 2 | Drug Info | [35] | |||
27 | Imidazopyridine derivative 4 | Drug Info | [35] | |||
28 | Imidazo[4,5-c]pyridine derivative 1 | Drug Info | [35] | |||
29 | Imidazo[4,5-c]pyridine derivative 2 | Drug Info | [35] | |||
30 | Isoxazole derivative 1 | Drug Info | [36] | |||
31 | Isoxazole derivative 2 | Drug Info | [36] | |||
32 | N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 | Drug Info | [35] | |||
33 | N-methylmethanesulfonamide derivative 1 | Drug Info | [36] | |||
34 | PMID27774822-Compound-Figure10Example1 | Drug Info | [36] | |||
35 | PMID27774822-Compound-Figure10Example19 | Drug Info | [36] | |||
36 | PMID27774822-Compound-Figure11Example5 | Drug Info | [36] | |||
37 | PMID27774822-Compound-Figure1Example20 | Drug Info | [36] | |||
38 | PMID27774822-Compound-Figure2Example1-1left | Drug Info | [36] | |||
39 | PMID27774822-Compound-Figure2Example1-1right | Drug Info | [36] | |||
40 | PMID27774822-Compound-Figure2Example4-3 | Drug Info | [36] | |||
41 | PMID27774822-Compound-Figure6Example2 | Drug Info | [36] | |||
42 | PMID27774822-Compound-Figure6Example3 | Drug Info | [36] | |||
43 | PMID27774822-Compound-Figure8Example5 | Drug Info | [36] | |||
44 | PMID27774824-Compound-Figure11Example1up | Drug Info | [35] | |||
45 | PMID27774824-Compound-Figure12Example1 | Drug Info | [35] | |||
46 | PMID27774824-Compound-Figure12Example10 | Drug Info | [35] | |||
47 | PMID27774824-Compound-Figure12Example61 | Drug Info | [35] | |||
48 | PMID27774824-Compound-Figure2Example4 | Drug Info | [35] | |||
49 | PMID27774824-Compound-Figure3Example18 | Drug Info | [35] | |||
50 | PMID27774824-Compound-Figure3Example7 | Drug Info | [35] | |||
51 | PMID27774824-Compound-Figure5Example13 | Drug Info | [35] | |||
52 | PMID27774824-Compound-Figure6Example12 | Drug Info | [35] | |||
53 | PMID27774824-Compound-Figure9Example2down | Drug Info | [35] | |||
54 | PMID27774824-Compound-Figure9Example2up | Drug Info | [35] | |||
55 | Pyrazolopyridine derivative 1 | Drug Info | [36] | |||
56 | Pyrazolopyridine derivative 2 | Drug Info | [36] | |||
57 | Pyrazolopyridine derivative 3 | Drug Info | [36] | |||
58 | Pyrazolopyridine derivative 4 | Drug Info | [36] | |||
59 | Pyrazolopyridine derivative 6 | Drug Info | [35] | |||
60 | Pyrazolopyridine derivative 7 | Drug Info | [35] | |||
61 | Pyrazolo[4,3-c]pyridine derivative 2 | Drug Info | [35] | |||
62 | Pyrimidopyridazinone derivative 2 | Drug Info | [35] | |||
63 | Pyrrole six-membered heteroaryl ring derivative 1 | Drug Info | [36] | |||
64 | Pyrrolo-pyrazine derivative 1 | Drug Info | [36] | |||
65 | Pyrrolo-pyrazine derivative 2 | Drug Info | [36] | |||
66 | Pyrrolo-pyrazine derivative 3 | Drug Info | [36] | |||
67 | Pyrrolo-pyrazine derivative 4 | Drug Info | [36] | |||
68 | Pyrrolo-pyridine derivative 3 | Drug Info | [36] | |||
69 | Pyrrolo[2,3-d]pyrimidine derivative 6 | Drug Info | [36] | |||
70 | Pyrrolo[2,3-d]pyrimidine derivative 7 | Drug Info | [36] | |||
71 | Pyrrolo[2,3-d]pyrimidine derivative 8 | Drug Info | [36] | |||
72 | Ruxolitinib derivative 2 | Drug Info | [35] | |||
73 | Tricyclic compound 1 | Drug Info | [35] | |||
74 | Tricyclic compound 11 | Drug Info | [36] | |||
75 | Tricyclic compound 2 | Drug Info | [35] | |||
76 | Tricyclic heterocycle derivative 1 | Drug Info | [36] | |||
77 | Tricyclic heterocycle derivative 2 | Drug Info | [35] | |||
78 | Tricyclic heterocycle derivative 5 | Drug Info | [36] | |||
79 | Tricyclic pyrrolopyridine compound 1 | Drug Info | [36] | |||
80 | AG490 | Drug Info | [37] | |||
81 | PNU156804 | Drug Info | [38] | |||
82 | R348 | Drug Info | [24] | |||
83 | 6-o-tolylquinazolin-2-amine | Drug Info | [39] | |||
84 | AD-412 | Drug Info | [25] | |||
85 | Atropisomer 1 | Drug Info | [40] | |||
86 | CMP-6 | Drug Info | [41] | |||
87 | NC1153 | Drug Info | [37] | |||
88 | PF-956980 | Drug Info | [25] | |||
89 | PMID15546730C2 | Drug Info | [42] | |||
90 | PMID21493067C1d | Drug Info | [43] | |||
91 | PMID24359159C19a | Drug Info | [44] | |||
92 | VX-467 | Drug Info | [25] | |||
93 | WHI-P154 | Drug Info | [45] | |||
94 | ZM-39923 | Drug Info | [46] | |||
Modulator | [+] 2 Modulator drugs | + | ||||
1 | Pacritinib | Drug Info | [3] | |||
2 | Tofacitinib | Drug Info | [1] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Tofacitinib | Ligand Info | |||||
Structure Description | Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6 | PDB:3LXK | ||||
Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | Yes | [47] |
PDB Sequence |
TIFEERHLKY
824 ISQLGKGNFG834 SVELCRYDPL844 GDNTGALVAV854 KQLQHSGPDQ864 QRDFQREIQI 874 LKALHSDFIV884 KYRGVSYGPG894 RQSLRLVMEY904 LPSGCLRDFL914 QRHRARLDAS 924 RLLLYSSQIC934 KGMEYLGSRR944 CVHRDLAARN954 ILVESEAHVK964 IADFGLAKLL 974 PLDKDYYVVR984 EPGQSPIFWY994 APESLSDNIF1004 SRQSDVWSFG1014 VVLYELFTYC 1024 DKSCSPSAEF1034 LRMMVPALSR1049 LLELLEEGQR1059 LPAPPACPAE1069 VHELMKLCWA 1079 PSPQDRPSFS1089 ALGPQLDML
|
|||||
|
LEU828
3.465
GLY829
2.959
LYS830
3.292
GLY831
3.515
GLY834
3.334
SER835
3.574
VAL836
3.184
ALA853
3.112
LYS855
3.714
VAL884
3.925
MET902
3.836
|
|||||
Ligand Name: ASP-015K | Ligand Info | |||||
Structure Description | Crystal structure of JAK3 in complex with peficitinib | PDB:6AAK | ||||
Method | X-ray diffraction | Resolution | 2.67 Å | Mutation | Yes | [48] |
PDB Sequence |
TIFEERHLKY
824 ISQLGKGNFG834 SVELCRYDPL844 GDNTGALVAV854 KQLQHSGPDQ864 QRDFQREIQI 874 LKALHSDFIV884 KYRGVSYQSL898 RLVMEYLPSG908 CLRDFLQRHR918 ARLDASRLLL 928 YSSQICKGME938 YLGSRRCVHR948 DLAARNILVE958 SEAHVKIADF968 GLAKLLPLDK 978 DVVREPGQSP990 IFWYAPESLS1000 DNIFSRQSDV1010 WSFGVVLYEL1020 FTYCDKSCSP 1030 SAEFLRMMRD1043 VPALSRLLEL1053 LEEGQRLPAP1063 PACPAEVHEL1073 MKLCWAPSPQ 1083 DRPSFSALGP1093 QLDML
|
|||||
|
||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
Biological Network Descriptors
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Chemokine signaling pathway | hsa04062 | Affiliated Target |
|
Class: Organismal Systems => Immune system | Pathway Hierarchy | ||
PI3K-Akt signaling pathway | hsa04151 | Affiliated Target |
|
Class: Environmental Information Processing => Signal transduction | Pathway Hierarchy | ||
Necroptosis | hsa04217 | Affiliated Target |
|
Class: Cellular Processes => Cell growth and death | Pathway Hierarchy | ||
Signaling pathways regulating pluripotency of stem cells | hsa04550 | Affiliated Target |
|
Class: Cellular Processes => Cellular community - eukaryotes | Pathway Hierarchy | ||
JAK-STAT signaling pathway | hsa04630 | Affiliated Target |
|
Class: Environmental Information Processing => Signal transduction | Pathway Hierarchy | ||
Th1 and Th2 cell differentiation | hsa04658 | Affiliated Target |
|
Class: Organismal Systems => Immune system | Pathway Hierarchy | ||
Th17 cell differentiation | hsa04659 | Affiliated Target |
|
Class: Organismal Systems => Immune system | Pathway Hierarchy | ||
Click to Show/Hide the Information of Affiliated Human Pathways |
Degree | 25 | Degree centrality | 2.69E-03 | Betweenness centrality | 3.05E-04 |
---|---|---|---|---|---|
Closeness centrality | 2.37E-01 | Radiality | 1.42E+01 | Clustering coefficient | 2.33E-01 |
Neighborhood connectivity | 3.76E+01 | Topological coefficient | 8.76E-02 | Eccentricity | 12 |
Download | Click to Download the Full PPI Network of This Target | ||||
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 2 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 213871. | |||||
REF 3 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 208712. | |||||
REF 4 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215830 | |||||
REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5677). | |||||
REF 6 | ClinicalTrials.gov (NCT02157012) Evaluation of the Condition of Rheumatoid Arthritis After Treatment. U.S. National Institutes of Health. | |||||
REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8315). | |||||
REF 8 | ClinicalTrials.gov (NCT02308163) A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs. U.S. National Institutes of Health. | |||||
REF 9 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8309). | |||||
REF 10 | ClinicalTrials.gov (NCT01830985) A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. | |||||
REF 11 | ClinicalTrials.gov (NCT03594227) ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis. U.S. National Institutes of Health. | |||||
REF 12 | ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health. | |||||
REF 13 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 14 | ClinicalTrials.gov (NCT04150341) A Randomized, Double-blind, Placebo-controlled, 3-period Crossover Study to Evaluate the Effects of Repeated Doses of Inhaled TD-8236 and Impact on Airway Responses Following Allergen Challenge in Patients With Asthma. U.S.National Institutes of Health. | |||||
REF 15 | ClinicalTrials.gov (NCT01994382) A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL). U.S.National Institutes of Health. | |||||
REF 16 | ClinicalTrials.gov (NCT04769869) A Single-blind, Randomized, Placebo-controlled 3 Part Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 Following Single and Multiple Ascending Doses and to Investigate the Anti-inflammatory Effect of Inhaled AZD4604. U.S.National Institutes of Health. | |||||
REF 17 | Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A?randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021 Sep;148(3):783-789. | |||||
REF 18 | ClinicalTrials.gov (NCT05006521) Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, PK, and PD of Single Ascending Doses of KN-002 in Healthy Subjects and Multiple Ascending Doses of KN-002 in Subjects With Mild Asthma, Moderate-Severe Asthma and COPD. U.S.National Institutes of Health. | |||||
REF 19 | ClinicalTrials.gov (NCT05206604) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, VEHICLE-CONTROLLED, FIRST-IN-HUMAN, MULTIPLE-DOSE STUDY, TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS, OF TOPICALLY ADMINISTERED PF-07295324 AND PF-07259955, IN HEALTHY ADULT PARTICIPANTS. U.S.National Institutes of Health. | |||||
REF 20 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 21 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5916). | |||||
REF 22 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006610) | |||||
REF 23 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008393) | |||||
REF 24 | Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. | |||||
REF 25 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049). | |||||
REF 26 | Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. | |||||
REF 27 | VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015 May;353(2):405-14. | |||||
REF 28 | Clinical pipeline report, company report or official report of Aclaris Therapeutics. | |||||
REF 29 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||||
REF 30 | The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324. | |||||
REF 31 | Clinical pipeline report, company report or official report of AstraZeneca | |||||
REF 32 | Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A?randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021 Sep;148(3):783-789. | |||||
REF 33 | Clinical pipeline report, company report or official report of Kinaset Therapeutics | |||||
REF 34 | Clinical pipeline report, company report or official report of Pfzer | |||||
REF 35 | Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. | |||||
REF 36 | Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. | |||||
REF 37 | Immunotherapy for De Novo renal transplantation: what's in the pipeline Drugs. 2006;66(13):1665-84. | |||||
REF 38 | Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002 Jan 15;99(2):680-9. | |||||
REF 39 | Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86. | |||||
REF 40 | Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41. | |||||
REF 41 | Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23. | |||||
REF 42 | Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6. | |||||
REF 43 | In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61. | |||||
REF 44 | Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58. | |||||
REF 45 | The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. | |||||
REF 46 | Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9. | |||||
REF 47 | Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol. 2010 Jul 16;400(3):413-33. | |||||
REF 48 | Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor. Bioorg Med Chem. 2018 Oct 1;26(18):4971-4983. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.